Meeting NewsVideo

VIDEO: Deepak L. Bhatt, MD, MPH, highlights interventional updates at AHA 2017

ANAHEIM, Calif. — In this video exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on five trials presented at the American Heart Association Scientific Sessions that advance understanding of pharmacologic therapy and prevention of renal outcomes during percutaneous coronary intervention.

Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Heart & Vascular Center, professor of medicine at Harvard Medical School and Cardiology Today’s Intervention chief medical editor, spotlights new data on rivaroxaban/aspirin vs. aspirin cost in a COMPASS subanalysis; dual antithrombotic therapy with dabigatran in patients with atrial fibrillation undergoing PCI in subgroup analyses of RE-DUAL PCI; benefits of aspirin in patients with previous PCI undergoing noncardiac surgery in a POISE-2 substudy; prasugrel vs. ticagrelor in PRAGUE-18; and strategies to prevent renal outcomes in PRESERVE.

“In a nutshell, those are some really interesting interventional trials that have been presented at AHA 2017, in what's been just a fantastic meeting,” Bhatt said.

ANAHEIM, Calif. — In this video exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on five trials presented at the American Heart Association Scientific Sessions that advance understanding of pharmacologic therapy and prevention of renal outcomes during percutaneous coronary intervention.

Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Heart & Vascular Center, professor of medicine at Harvard Medical School and Cardiology Today’s Intervention chief medical editor, spotlights new data on rivaroxaban/aspirin vs. aspirin cost in a COMPASS subanalysis; dual antithrombotic therapy with dabigatran in patients with atrial fibrillation undergoing PCI in subgroup analyses of RE-DUAL PCI; benefits of aspirin in patients with previous PCI undergoing noncardiac surgery in a POISE-2 substudy; prasugrel vs. ticagrelor in PRAGUE-18; and strategies to prevent renal outcomes in PRESERVE.

“In a nutshell, those are some really interesting interventional trials that have been presented at AHA 2017, in what's been just a fantastic meeting,” Bhatt said.

    See more from American Heart Association Scientific Sessions